Pathogenetic rationale and the first experience of using direct high - volume endolymphatic therapy in the treatment of patients with COVID-19 and bilateral polysegmental interstitial pneumonia

The use of natural high - volume endolymphatic therapy in treating severe forms of lung damage in patients with COVID-19 with the addition of a secondary infection is pathogenetically substantiated. The results of its implementation in 10 seriously ill patients with this pathology were analyzed. On days 1-2, after the start of endolymphatic therapy, the patients improved gas exchange, decreased respiratory failure symptoms, and oxygen saturation in the blood increased to 95-97%. The need for artificial lung ventilation disappeared, and on the 7-10th day, the patients switched to spontaneous breathing. Body temperature, heart rate, and blood pressure returned to normal already on the 2-3rd day. On the 3-4th day, appetite improved, and the sense of smell was restored. There were no lethal outcomes.

COVID-19, coronavirus infection, COVID-19, lymphatic system, endolymphatic therapy, bilateral pneumonia